PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.02%
Revenue growth under 50% of MRVL's 1.34%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-3.26%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-3.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-4.06%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-0.75%
Negative net income growth while MRVL stands at 209.30%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-0.53%
Negative EPS growth while MRVL is at 300.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-1.07%
Negative diluted EPS growth while MRVL is at 300.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.09%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
38.46%
OCF growth above 1.5x MRVL's 23.98%. David Dodd would confirm a clear edge in underlying cash generation.
1040.43%
FCF growth above 1.5x MRVL's 41.79%. David Dodd would verify if the firm’s strategic investments yield superior returns.
68.63%
10Y revenue/share CAGR above 1.5x MRVL's 27.70%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
13.51%
5Y revenue/share CAGR under 50% of MRVL's 44.55%. Michael Burry would suspect a significant competitive gap or product weakness.
19.91%
3Y revenue/share CAGR under 50% of MRVL's 81.86%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
103.13%
10Y OCF/share CAGR in line with MRVL's 95.20%. Walter Schloss would see both as similarly efficient over the decade.
-1.85%
Negative 5Y OCF/share CAGR while MRVL is at 10.17%. Joel Greenblatt would question the firm’s operational model or cost structure.
35.56%
3Y OCF/share CAGR under 50% of MRVL's 391.73%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
227.96%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
16.17%
Positive 5Y CAGR while MRVL is negative. John Neff might view this as a strong mid-term relative advantage.
27.56%
Below 50% of MRVL's 112.63%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
81.65%
10Y equity/share CAGR at 50-75% of MRVL's 115.82%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
68.77%
5Y equity/share CAGR at 50-75% of MRVL's 122.03%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
101.75%
3Y equity/share CAGR 1.25-1.5x MRVL's 70.16%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
341.28%
Stable or rising dividend while MRVL is cutting. John Neff sees a strong advantage in consistent shareholder returns vs. a struggling peer.
99.61%
5Y dividend/share CAGR above 1.5x MRVL's 0.49%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
37.84%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
1.02%
AR growth is negative/stable vs. MRVL's 7.70%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
4.80%
Inventory growth well above MRVL's 4.86%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.26%
Asset growth 1.25-1.5x MRVL's 1.62%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
4.34%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
0.03%
We have some new debt while MRVL reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-1.26%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-1.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.